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*




      Embryonic stem cells (ESCs) are pluripotent, self-renewing cells. These cells can be used in applications such as 
cell therapy, drug discovery, disease modelling, and the study of cellular differentiation. In this experimental study 
embryonic stem cells cultured in the laboratory and were amplified. Total RNA was extracted from cells and 
converted to cDNA. The replication factor Oct3/4 gene was amplified by reverse transcription-polymerase chain 
reaction (RT-PCR) and cloned into the pTZ57R/T vector. Legated product had been transformed into susceptible 
bacteria and transformed bacteria were screened on a selective medium. Plasmids extracted from bacteria and 
enzyme digestion to confirm the sequencing was performed. Results of enzyme digestion were sequenced. Cloned 
gene can prepare a gene cassette to produce stem cells from somatic cell. 
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INTRODUCTION 
     Human ES cells may become an unlimited source 
of cells or tissues for transplantation therapies 
involving organs or tissues such as liver, nervous 
system, pancreas and blood. Despite a tremendous 
interest in ES cells, relatively little is known about 
what defines their pluripotency and what drives ES 
cells to differentiate into specific cell types. The 
development of the mammalian embryo is controlled 
by regulatory genes, some of which regulate the 
transcription of other genes [1 & 2]. These regulators 
activate or repress patterns of gene expression that 
mediate phenotypic changes during stem cell 
differentiation. Oct4 (also known as Oct-3) belongs to 
the POU (Pit- Oct-Unc) transcription factor family 
[2].The POU family of transcription factors can 
activate the expression of their target genes through 
binding an octameric sequence motif of an 
AGTCAAAT consensus sequence [1-3]. Recent 
evidence indicates that Oct4 is almost exclusively 
expressed in ES cells [4 & 5]. During embryonic 
development, Oct4 is expressed initially in all 
blastomeres. Subsequently, its expression becomes 
restricted to the ICM and down-regulated in the TE 
and the primitive endoderm. At maturity, Oct4 
expression becomes confined exclusively to the 
developing germ cells [3- 6]. 
     These cells can re-enter the developing embryo and 
contribute to all cell types of     the embryo including 
germ line. Loss of pluripotency in ES cells is often 
accompanied by Oct4 down-regulation. Oct4 deficient 
mouse embryos fail to develop beyond the blastocyst 
stage due to the lack of pluripotent ICM [7], 
suggesting the critical role of Oct4 in maintaining ES 
cell pluripotency in vivo. However, Oct4 is not the 
only master gene that controls ES cell pluripotency. 
Oct3/4 is a transcription factor known to play a key      
role in the maintenance and self-renewal of 
pluripotent cells. Biochemically, Oct4 has been shown 
to be a DNA-binding protein with a bipartite 
POU/homeodomain encoded by a 324-amino acid 
open reading frame [8]. Oct4 relies on two trans-
activation domains flanking the DNA-binding domain 
to exert its transcription activities [9].  
     Oct4 protein is synthesized in the cytosol and 
transported into the nuclei via a typical nuclear 
localization signal [10]. The nuclear localization 
signal of Oct4 is required for its transcription activity, 
and its ablation leads to the generation of a dominant-
negative form of Oct4, which is capable of inducing 
ES cell differentiation by interfering with wild-type 
Oct4 activity [10]. ES cells cannot be established from 
Oct3/4 knockout embryos, while repression of Oct3/4 
in ES cells results in differentiation into trophoblast-
like cells, demonstrating the essential role played by   
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Oct3/4 in the maintenance of pluripotency.  
     Interestingly, Oct3/4 is also important in promoting 
differentiation, as its over-expression by as little as 
50% results in differentiation of ES cells into 
mesoderm and endoderm. Together, these findings 
suggest that Oct3/4 expression levels require very 
tight regulation in ES cells. Oct3/4 has been shown to 
have a large number of target genes, many of which 
also possess regulatory elements for Sox2 and Nanog. 
Such genes are frequently up-regulated or down-
regulated in ES cells, and encode proteins involved in 
ES cell signalling. Oct3/4 is known to co-operate with 
Sox2 to regulate a number of genes, including Sox2 
and Oct3/4 in a positive feedback loop and Nanog. 
Binding sites for both Oct3/4 and Sox2 have also been 
found in a number of other genes specifically 
expressed in ES cells including Fbx15 and Lefty. In 
addition, two regulatory elements exist, which act as 
stem-cell-specific enhancers of the Oct3/4 gene. Many 
regulators are recruited to these elements; and shifts in 
the balance between positive and negative regulators 
may give rise to variation in the levels of Oct3/4 
expression, in response to external stimuli. Liver 
receptor homologue 1 (Lrh1) acts as a positive 
regulatory factor for Oct3/4 while germ cell nuclear 
factor (Gcnf) acts as a repressor by recruiting Dnmt3 
and promoting methylation of the Oct3/4 promoter [9, 
10]. 
 
MATERIALS & METHODS 
Cell culture 
     In this study, human embryonic stem line, (hSCT1; 
Stem cell technology research centre,  Tehran, Iran)  
was cultured in DMEM-F12 supplemented with 20% 
knockout serum replacement, 2 mM L-gluatamine, 
1% nonessential amino acid, and 20  ng/ml human 
bFGF (all from Invitrogen), and 0.1 mM 2-
mercaptoethanol (Sigma). Primary mouse embryonic 
fibroblasts (MEFs) were used as the feeder cells in 
passages 2-4. Monolayer of feeders were grown in 
Dulbecco modified Eagle medium (DMEM; GIBCO) 
supplemented with 15% fetal  calf serum (FCS; 
GIBCO), 2 mM L-glutamine (GIBCO), 25 U/mL 
penicillin,  and 25 µg/mL streptomycin (GIBCO), to 
confluence in a T-flask and treated with 10 µg/mL 
mitomycin-C (Sigma) for  2 h. After treatment, cells 
were washed extensively in PBS, detached with 
0.25% trypsin–ethylene-diamine tetra-acetic acid 
(EDTA), and re-plated in gelatin-coated tissue culture 
dishes. 
     hESC experiments were performed on passage 12 
from initial  establishment. The cells were passaged 
every 3–5 days with 1 mg/ml collagen IV 
(Invitrogen). After PBS washing, the cells were 
dispersed by scraping and passaged on fresh 
inactivated MEFs with above mentioned culture 
medium. 
 
Cloning of OCT3/4 gene 
     Total RNA of cells was extracted by RNA fast kit 
(provided by National Research Center of Genetic 
Engineering and Biotechnology, Tehran, Iran) based 
on using guanidine isothiosyanate. The efficiency of 
RNA extraction was confirmed by 1% agarose gel 
electrophoresis. Then, total RNA was stored in -70°C 
until use time. For accomplishment of reverse 
transcription (RT) reaction to obtain equivalent 
cDNA, we used expanded first strand cDNA synthesis 
kit (Roche Molecular Biochemicals, Germany). In this 
kit, the RNase activity of reverse transcriptase enzyme 
(MuLv, moloney murin leukemia virus) has been 
eliminated due to existence of a mutation in C-
terminus of RT enzyme. The sequence of Oct3/4 gene 
related to Human embryonic stem cell was gained 
from Gen Bank followed by two pairs of primers were 
designed(Table 1).The  primers were used to amplify 
and clone of the complete sequence of Oct3/4 gene. 
 
Table1. The oligonucleotide primers used in the PCR assay 
Primers Sequence 
Forward: 5 - CATAT           T   TT   -3 
Reverse: 5 -          TTT   T   T           -3 
 
     The annealing temperature for primers was set at 
62°C. The extension time was 60 seconds. B actin 
gene in all reactions was used as internal control. 
Amplification was made in a total volume of 25 μl of 
reaction mixture containing 1µl of genomic DNA , 2.5 
μl of 10× P R buffer, 1.5 µl of MgCl2 (50 mM), 200 
μM dNTP(10mM), 1.5 µl of each primer (10 pmol) 
and 0.25 µl of Taq polymerase (5 unit/µl). By adding 
double-distilled water, the reaction mixture reached      
the Final volume 25 µl. A total of 32 cycles was 
performed with the first denaturation at 95 °C for 5 
min, then 30 cycles at 95 °C for 30 seconds, 67 °C for 
30 seconds and 72 °C for 30 seconds, and the final 
extension at 72 °C for 5 min. The amplified products 
were analyzed by electrophoresis with a 1% agarose 
gel followed by ethidium bromide staining and UV-
transilluminator visualization. 
     After the end of reaction, the amount of 7 µl of the 
product was used to run on 1% agarose gel 
electrophoresis and then staining results were 
compared with marker 1kbp (Fermentase). After all 
proprietary products, PCR product purified and with 
the cloning vector pTZ57R / T were Lygated and 
transformed into E. coli DH5α.  mpicillin selection 
Journal of Paramedical Sciences (JPS)                                               Winter 2011 VOl.2, No.1 ISSN 2008-4978 
   
43 
and some control tests ensured the presence of the 
recombinant plasmid. PCR with specific primers was 
performed for some of the cloned hosts. The 
recombinant clonies in PCR reaction were sent for 
sequencing.  
      
RESULTS 
Result of Cell culture 
The results of embryonic stem cells culture has been 
shown in Figure 1. 
  
 
Figure 1. hSCT1 human embryonic stem cell line. 
 
Results of Gene cloning 
      Proliferation area which code human Oct3/4 gene 
was provided in the presence of desired primers and 
1070 bp PCR product of human Oct3/4 genes was 
obtained.  
The 1070-bp PCR product was cloned in vector 
pTZ57R/T. PCR reaction of the clonies on selective 
culture indicates some of these recombinant clonies 
specific for hosts by using Oct3/4 primers. Lane M: 
DNA molecular weight marker, Lane 1: Recombinant 
clonies, Lane 2: Non recombinant clonies (Figure 2). 
Results of the sequencing on plasmids extracted from 
recombinant clonies and comparison with gene data 
bank confirmed cloning of these genes. 
 
Figure 2. Polymerase chain reaction of the cloned  
 
DISCUSSION 
      iPS cells, generated by introduction of Oct3/4, 
Sox2, Klf4 and c-Myc transcription factors into 
fibroblasts, share many properties with ES cells. 
Additionally, contribution of iPS cells to live adult 
chimeric animals and germline transmission clearly 
demonstrate that re-programming, to cells very similar 
to pluripotent ES cells, was achieved. Pluripotent stem 
cells (ESCs and iPSCs) are of great interest for basic 
research and clinical applications because they are 
uniquely capable of self-renewal and differentiation 
into a large number of cell types. These cells make it 
possible for the first time to analyze the epigenetic 
control of pluripotence and differentiation. 
      Yamanaka and co-workers surprised the scientific 
community when they reported that both mouse 
embryonic fibroblasts and tail tip fibroblasts could be 
reprogrammed to a pluripotent state similar to that 
observed in embryonic stem (ES) cells, by retroviral 
transduction of just four genes. The discovery of these 
‘induced pluripotent stem (iPS) cells’ was generally 
regarded as a major development in stem cell research 
and gave new insights into the pathways involved in 
the maintenance of pluripotency. Due to the 
complexity of genetic and epigenetic changes 
involved in cell differentiation, it had been doubted if 
it would ever be possible to reprogramme somatic 
cells to pluripotency. With the first successful cloning 
experiments in mammals, it was verified that such 
reprogramming was indeed possible. However, the 
landmark discovery by Takahashi and Yamanaka less 
than a decade later signalled a development, which 
few expected so soon. 
     By definition, pluripotency is the ability of a cell to 
give rise to all cell types of an adult organism, without 
the self-organising capability to form the whole 
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organism. In vivo, pluripotency is observed in early 
embryos while in vitro, pluripotency may be 
maintained in ES cells. ES cells may be harvested 
from the inner cell mass (ICM) of blastocyst stage 
embryos. These cells, which were first isolated from 
mouse embryos, can proliferate indefinitely and 
possess the potential to develop in an unrestricted 
manner. 
      In culture, the pluripotency of mouse ES cells 
must be maintained by addition of factors such as 
leukaemia inhibitory factor (LIF), which promote 
proliferation while preventing differentiation. Human 
ES cells lines have also been generated, and their 
potential as donor sources of specialised cells in cell 
transplantation therapies has been widely 
acknowledged. 
      However, some major concerns remain for ES cell 
transplantation. Tissue rejection due to the patients, 
immune response represents a real limitation of the 
use of ES cells for transplantation. Another concern is 
that in the process of isolating ES cells, human 
embryos are inevitably destroyed. This has been a 
source of constant controversy since the development 
of the first human ES cell lines, and it has become an 
important ethical and political issue. These problems 
may, however, be overcome by reprogramming 
differentiated cells to an ES cell-like, pluripotent state. 
Such cells could be customised for individual patients 
and used in the treatment of disease. 
      Improvements in methodologies for detecting gene 
expression in the early embryo have led to the 
identification of several genes that may be involved in 
the regulation of early developmental events. These 
include genes encoding growth factors, their 
receptors, and numerous transcription factors, among 
which Oct4 seems to play a major role [11]. Oct4 
(also known as OTF3, POU5F1) is a POU-domain, 
octamerbinding transcription factor expressed in both 
mouse and human embryonic stem cells (ESCs) and 
primordial germ cells (PGCs). Oct4 expression is 
necessary for the maintenance of pluripotentiality in 
ESC and PGC and it is down-regulated in all 
differentiated somatic cell types in vitro as well as in 
vivo [3]. 
      Decreased Oct4 gene expression is accomplished 
via increased DNA methylation and structural changes 
involving the immediate upstream regulatory 
region[12]. The Oct4 gene is un-methylated in the 
blastula stage and subsequently undergoes de novo 
methylation at 6.5 days postcoitum, remaining 
modified in all adult tissues [11 & 12]. A similar 
pattern was found in human EC cell lines [2]. A 
similar relationship between expression and 
methylation pattern was recently found in in vivo 
samples of GCTs. In addition to its role in the 
maintenance of pluripotentiality, Oct4 may also play a 
role in maintenance of viability of the mammalian 
germline, functioning as a ‘stem cell survival’ factor 
[14 & 15]. Primordial germ cells lacking Oct4 
expression have been shown to undergo apoptosis 
rather than differentiation [16]. 
      Variations in Oct4 levels are responsible for most 
failures in somatic cell cloning [17 & 18]. These 
findings imply a possible different function of Oct4 in 
ESCs and PGCs, which may have an impact on the 
understanding of its role in the pathogenesis of GCTs. 
The fundamental role of Oct4 expression in the 
preservation of pluripotent cells in the inner cell mass 
of blastocysts has been demonstrated by specific 
disruption of the Oct4 gene in mice, showing that 
Oct4 deficiency in the mouse embryo results in failure 
of the inner cell mass to develop [11]. Moreover, a 
critical amount of Oct4 is needed for the self-renewal 
of normal ESCs, while both up- and down-regulation 
of Oct4 expression are responsible for divergent 
differentiation of these pluripotent cells [13]. 
     Quantitative analyses in mouse ESCs show that 
high levels of Oct4 expression cause differentiation 
into primitive endoderm and mesoderm, whereas low 
levels determine loss of pluripotency and 
differentiation towards trophectoderm [20]. Recently, 
these results have been confirmed by analyses with 
Oct4-specific short interfering RNA, inducing 
knockdown of Oct4 in both mouse and human cell 
lines [14&15].Since Oct4 was first identified in EC 
cells and is expressed in all EC cell lines and because 
Oct4 confers pluripotentiality, as well as cell survival, 
to germ cells, the aberrant expression of this 
transcription factor might contribute to tumourigenesis 
in GCTs [3]. 
Indeed, Gidekel et al found that the level of Oct4 
expression dictated the oncogenic potential of ESCs in 
a dose-dependent manner [3]. High levels of Oct4 
increased the malignant potential of mouse ESC 
derived tumours, while Oct4 inactivation induced 
regression of the malignant component. It must be 
kept in mind that these tumours have a limited 
developmental potency. They never show a seminoma 
or choriocarcinoma component, and are 
predominantly composed of teratoma, and possibly 
yolk sac tumour upon extensive in vivo growth [16]. 
Oct4, therefore, plays a significant role in the 
malignant behaviour of ESC cells. 
      In ES cells, Oct4 appears to regulate cell fate in a 
dosage-dependent fashion [17]. Using a conditional 
expression and repression System demonstrated that 
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the level of Oct4 activity specifies three distinct fates 
of ES cells: 1) a_2-fold increase in expression turns 
ES cells into primitive endoderm and mesoderm; 2) 
repression of Oct4 induces the formation of 
trophectoderm; and 3) only an optimal amount of 
Oct3/4 can sustain stem cell self-renewal. These 
results suggest that ES cells must possess a network of 
regulators to keep Oct4 expression at the optimal level 
to ensure pluripotency [4]. How many transcription 
factors are involved in the regulation of Oct4 
expression? This was the question asked by several 
groups in light of the observation that Oct4 must be 
maintained in a narrow range of expression levels to 
ensure stem cell pluripotency. The discovery of 
Nanog offered a clear candidate for Oct4 regulation. 
Named after Tir Nan Og (the Land of the Young), 
Nanog was discovered based on its ability to sustain 
stem cell self-renewal in the absence of LIF [17]. 
Although it was originally believed that Nanog 
prevents ES cell from differentiation in the absence of 
LIF by repressing the expression of differentiation 
genes, a simple reporter assay demonstrated that 
Nanog possesses two potent transactivators [18 & 19], 
suggesting that Nanog could be an activator of Oct4 
expression. Indeed, Nanog behaves as a strong 
activator of the Oct4 promoter, thus participating in 
the regulation of Oct4 expression in ES cells [18]. 
In the last decade, a number of methods have been 
found to induce pluripotency artificially in somatic 
cells, including somatic cell nuclear transfer (SCNT) 
and cell fusion. Much of the research in this area has 
been carried out with mice, but the ultimate goal of 
stem-cell scientists remains the production of patient-
specific pluripotent cells and their use in treatment of 
disease. Because both SCNT and cell fusion have 
posed technical and ethical problems as methods of 
reprogramming somatic cells, Takahashi and 
Yamanaka’s method of reprogramming by defined 
factors has been hailed as the ‘holy grail’ of stem cell 
research. This method circumvents many of the 
problems associated with both SCNT and cell fusion 
and is regarded as the method with the best potential 
for producing patient-specific pluripotent stem cells 
for use in regenerative medicine [11].  
      Since the initial discovery of mouse iPS cells by 
Takahashi and Yamanaka, research in this area has 
advanced at an astonishing rate. In just over a year, 
the technology used to re-programme mouse cells has 
been successfully extended to human cells, while 
some of the initial problems with mouse iPS cells, 
including tumourigenicity have been partly addressed. 
Nevertheless, extensive research is still required with 
mouse iPS cells before any potential therapeutic use 
of human iPS cells is realised. The cause of the low 
efficiency of iPS induction remains to be determined. 
In addition to gene activation by expression of 
transcription factors, epigenetic remodelling plays a 
key role in induction of cellular pluripotency. A 
greater understanding of this mechanism will be 
necessary to improve the efficiency of iPS cell 
generation. Moreover, retroviral transduction involves 
random integration into the genome and consequently 
poses a risk of mutagenesis. The future use of 
alternative gene delivery systems or small molecules, 
which can replace retroviral gene products, may 
circumvent this problem. 
     Also, if iPS cells are to be used clinically, methods 
to direct differentiation and integrate them into tissues 
are still required. Despite this, however, iPS cells 
represent one of the best hopes for producing patient-
specific stem cells for cell-based therapies. 
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